NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the period from October 1, 2023, to December 31, 2023, our executive officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title | Action | Date | Trading Arrangement | Total Shares Authorized to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* · Non-Rule 10b5-1** | |||||
| George Morrow | Adopt | 12/14/2023 | X | 40,000 | 11/15/2024 |
| (Director) | |||||
| Eric Benevich | Terminate (1) | 11/30/2023 | X | 131,341 | 12/31/2023 |
| (Chief Commercial Officer) | Adopt | 11/29/2023 | X | 169,818 | 11/27/2024 |
| Ingrid Delaet | Adopt | 11/29/2023 | X | 30,000 | 9/7/2025 |
| (Chief Regulatory Officer) | |||||
| Leslie Norwalk | Adopt | 11/28/2023 | X | 9,106 | 11/28/2024 |
| (Director) | |||||
| Shalini Sharp | Adopt | 11/27/2023 | X | 1,106 | 5/31/2024 |
| (Director) | |||||
| Richard Pops | Adopt | 11/21/2023 | X | 42,100 | 11/30/2024 |
| (Director) | |||||
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
**Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
(1) On November 30, 2023, Eric Benevich, Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1 (the “Benevich 10b5-1 Plan”). The Benevich 10b5-1 Plan was entered into on February 23, 2022, with an expiration date of December 31, 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.